Skip to main content

Link Between n-3 LCPUFA, Eczema Varies by Maternal COX1 Genotype

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 4, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Sept. 4, 2024 -- The association of prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) with the risk for childhood atopic dermatitis (AD) varies based on the maternal cyclooxygenase-1 (COX1) genotype, according to a study published online Aug. 28 in JAMA Dermatology.

Liang Chen, from Herlev and Gentofte Hospital in Copenhagen, Denmark, and colleagues examined the association of n-3 LCPUFA supplementation during pregnancy with the risk for childhood AD overall and by maternal COX1 genotype. A total of 736 pregnant women at 24 weeks of gestation were randomly assigned to n-3 LCPUFA (fish oil) or placebo (olive oil) until one-week postpartum; 635 children completed clinical follow-up.

The researchers observed an association between pregnancy n-3 LCPUFA supplementation and lower urinary thromboxane A2 metabolites at age 1 year (β = −0.46), which was also associated with the COX1 rs1330344 genotype (β per C allele, 0.47). There were no associations for n-3 LCPUFA supplementation or the maternal COX1 genotype with the risk for childhood AD until age 10 years; however, evidence of an interaction between these variables was seen. The risk for AD was lower in the n-3 LCPUFA group versus the placebo group among mothers with the TT genotype, while no association was seen for mothers with the CT genotype. An increased risk was seen for offspring of mothers with the CC genotype.

"These findings support use of a personalized prevention strategy for reducing the burden of AD in childhood by only providing n-3 LCPUFA supplementation to pregnant mothers carrying the COX1 rs1330344 TT genotype," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Early-Onset Pediatric Atopic Dermatitis Tied to Higher Risk for Uveitis

WEDNESDAY, April 23, 2025 -- Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published online April 3 in...

American Academy of Dermatology, March 7 to 11

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health...

AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof

FRIDAY, March 14, 2025 -- Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.